Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Heart Failure VII: Nursing Interventions

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...

Heart Failure I: Introduction

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cardiac Implantable Electronic Devices in Oncology Patients: Challenges and Management.

Journal of cardiovascular electrophysiology·2026

Same author

GLP-1 Receptor Agonists: From Glycaemic Control to Cardio-Reno-Metabolic Disease Modification.

European heart journal. Quality of care & clinical outcomes·2026

Same author

Ferroptosis-Associated Fibroblast Activation and Transcriptional Remodelling in Human Heart Failure: A Proof-of-Concept Study.

European journal of clinical investigation·2026

Same author

Evaluation and management of recent onset cardiomyopathy in the current era of heart failure therapeutics: a clinical consensus statement of the Heart Failure Association of the ESC.

ESC heart failure·2026

Same author

Sodium-glucose cotransporter 2 inhibitors across cardio-reno-metabolic disease and body mass index: a meta-analysis of randomized controlled trials.

European heart journal. Quality of care & clinical outcomes·2026

Same author

Early Recovery of Oxygen Kinetics in Heart Failure: A Systematic Review of Oxygen Kinetics During the First Minute of Recovery after Cardiopulmonary Exercise Testing in Heart Failure.

Current cardiology reviews·2026

Search research articles

Related Experiment Videos

Hyponatremia in heart failure.

Dimitrios Farmakis¹, Gerasimos Filippatos, John Parissis

¹Second Department of Cardiology, Heart Failure Unit, Attikon University Hospital, Athens, Greece. dimitrios_farmakis@yahoo.com

Heart Failure Reviews

|September 2, 2008

Summary

Hyponatremia, common in heart failure patients, is often resistant to treatment. Vasopressin antagonists effectively correct low serum sodium levels, but their impact on long-term heart failure prognosis requires further investigation.

Related Experiment Videos

Area of Science:

Cardiology
Nephrology
Internal Medicine

Background:

Hyponatremia is a frequent complication in hospitalized heart failure patients.
It can manifest across various fluid status conditions (hypovolemic, hypervolemic, euvolemic).
Current therapies often fail to correct hyponatremia effectively.

Purpose of the Study:

To evaluate the efficacy of vasopressin antagonists in correcting hyponatremia in heart failure.
To investigate the potential impact of normalized serum sodium on long-term prognosis in these patients.

Main Methods:

This study focuses on the clinical outcomes of heart failure patients with hyponatremia.
Utilizes vasopressin antagonists as a therapeutic intervention.
Observational analysis of serum sodium normalization and long-term prognosis.

Main Results:

Vasopressin antagonists demonstrate effectiveness in correcting hyponatremia.
The correction of serum sodium levels is achievable with this class of drugs.

Conclusions:

Hyponatremia is a significant prognostic indicator in heart failure.
Vasopressin antagonists offer a viable strategy for managing hyponatremia.
Further research is needed to confirm if sodium normalization improves long-term heart failure outcomes.